EDTA Inhibits Biofilm Formation, Extracellular Vesicular Secretion, and Shedding of the Capsular Polysaccharide Glucuronoxylomannan by Cryptococcus neoformans

Applied and Environmental Microbiology

Volumn 78, Issue 22, 2012, Pages 7977-7984

  Robertson, Emma J ^a,b   Wolf, Julie M ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL DRUGS; ANTIMICROBIAL COMPOUNDS; BIOFILM FORMATION; BIOFILM GROWTH; BIOFILM MATRIX; CAPSULAR POLYSACCHARIDES; CHRONIC INFECTION; CRYPTOCOCCUS NEOFORMANS; DIVALENT CATION; DIVALENT METALS; EXTRACELLULAR; FLUCONAZOLE; FUNGAL PATHOGEN; GROWTH MEDIUM; IN-VIVO; INHIBITORY EFFECT; INTRA-CRANIAL PRESSURE; NEOFORMANS; POTENTIAL MECHANISM; VORICONAZOLE;

MAGNESIUM; MICROORGANISMS; PATHOGENS; PHYSIOLOGY; POSITIVE IONS;

BIOFILMS;

CALCIUM; DIVALENT CATION; EDETIC ACID; GLUCURONOXYLOMANNAN; MAGNESIUM; POLYSACCHARIDE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BIOFILM; EDTA; FUNGUS; INFECTIVITY; INHIBITION; PATHOGEN; POLYSACCHARIDE; SECRETION; SUBLETHAL EFFECT;

ARTICLE; BIOFILM; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PHYSIOLOGY; SECRETORY VESICLE;

BIOFILMS; CALCIUM; CATIONS, DIVALENT; CRYPTOCOCCUS NEOFORMANS; EDETIC ACID; MAGNESIUM; POLYSACCHARIDES; SECRETORY VESICLES;

FILOBASIDIELLA NEOFORMANS;

EID: 84868626629     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.01953-12     Document Type: Article

References (33)

1. Bosio S, et al. 2012. Mycobacterium fortuitum prosthetic valve endocarditis: a case for the pathogenetic role of biofilms. Cardiovasc. Pathol. 21: 361-364.
2. Devine DA, et al. 2007. Inhibition of biofilms associated with dentures and toothbrushes by tetrasodium EDTA. J. Appl. Microbiol. 103:2516-2524.
3. Donlan RM. 2000. Role of biofilms in antimicrobial resistance. ASAIO J. 46:S47-S52. doi:10.1097/00002480-200011000-00037.
4. Fries BC, et al. 2005. Phenotypic switching of Cryptococcus neoformans can produce variants that elicit increased intracranial pressure in a rat model of cryptococcal meningoencephalitis. Infect. Immun. 73:1779-1787.
5. Ghannoum MA, Isham N, Jacobs MR. 2011. Antimicrobial activity of B-Lock against bacterial and Candida spp. causing catheter-related bloodstream infections. Antimicrob. Agents Chemother. 55:4430-4431.
6. Graybill JR, et al. 2000. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin. Infect. Dis. 30:47-54.
7. Guggenbichler JP, Assadian O, Boeswald M, Kramer A. 2011. Incidence and clinical implication of nosocomial infections associated with implantable biomaterials- catheters, ventilator-associated pneumonia, urinary tract infections. GMS Krankenhhyg. Interdiszip. 6:Doc18. doi:10.3205/dgkh000175.
8. Karunakaran E, Mukherjee J, Ramalingam B, Biggs CA. 2011. "Biofilmology": a multidisciplinary review of the study of microbial biofilms. Appl. Microbiol. Biotechnol. 90:1869-1881.
9. Kite P, Eastwood K, Sugden S, Percival SL. 2004. Use of in vivogenerated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. J. Clin. Microbiol. 42:3073-3076.
10. Lopez-Ribot JL. 2005. Candida albicans biofilms: more than filamentation. Curr. Biol. 15:R453-R455. doi:10.1016/j.cub.2005.06.020.
11. Mah TF, O'Toole GA. 2001. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9:34-39.
12. Martinez LR, Casadevall A. 2007. Cryptococcus neoformans biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and UV light. Appl. Environ. Microbiol. 73:4592-4601.
13. Martinez LR, Casadevall A. 2006. Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system. Infect. Immun. 74:6118-6123.
14. Martinez LR, Casadevall A. 2005. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect. Immun. 73:6350-6362.
15. Martinez LR, Casadevall A. 2006. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 50:1021-1033.
16. Moscoso M, Garcia E, Lopez R. 2009. Pneumococcal biofilms. Int. Microbiol. 12:77-85.
17. Nimrichter L, et al. 2007. Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot. Cell 6:1400-1410.
18. Parker SL, Anderson WN, Lilienfeld S, Megerian JT, McGirt MJ. 2011. Cerebrospinal shunt infection in patients receiving antibioticimpregnated versus standard shunts. J. Neurosurg. Pediatr. 8:259-265.
19. Percival SL, et al. 2005. Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm. Infect. Control Hosp. Epidemiol. 26:515-519.
20. Raad II, et al. 2008. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm. Int. J. Antimicrob. Agents 32:515-518.
21. Raad I, et al. 2003. In vitro and ex vivo activities of minocycline and EDTA against microorganisms embedded in biofilm on catheter surfaces. Antimicrob. Agents Chemother. 47:3580-3585.
22. Raad I, Hanna H, Dvorak T, Chaiban G, Hachem R. 2007. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob. Agents Chemother. 51:78-83.
23. Ramage G, Martinez JP, Lopez-Ribot JL. 2006. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 6:979-986.
24. Ramage G, VandeWalle K, Lopez-Ribot JL, Wickes BL. 2002. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol. Lett. 214:95-100.
25. Ramage G, Wickes BL, Lopez-Ribot JL. 2007. Inhibition on Candida albicans biofilm formation using divalent cation chelators (EDTA). Mycopathologia 164:301-306.
26. Robertson EJ, Casadevall A. 2009. Antibody-mediated immobilization of Cryptococcus neoformans promotes biofilm formation. Appl. Environ. Microbiol. 75:2528-2533.
27. Rodrigues ML, et al. 2007. Vesicular polysaccharide export in Crypto-coccus neoformans is a eukaryotic solution to the problem of fungal transcell wall transport. Eukaryot. Cell 6:48-59.
28. Stewart PS, Costerton JW. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138.
29. Vecchiarelli A. 2000. Immunoregulation by capsular components of Cryptococcus neoformans. Med. Mycol. 38:407-417.
30. Venkatesh M, Rong L, Raad I, Versalovic J. 2009. Novel synergistic antibiofilm combinations for salvage of infected catheters. J. Med. Microbiol. 58:936-944.
31. Walsh TJ, Schlegel R, Moody MM, Costerton JW, Salcman M. 1986. Ventriculoatrial shunt infection due to Cryptococcus neoformans: an ultrastructural and quantitative microbiological study. Neurosurgery 18: 373-375.
32. Wolf JM, Rivera J, Casadevall A. 2012. Serum albumin disrupts Cryptococcus neoformans and Bacillus anthracis extracellular vesicles. Cell. Microbiol. 14:762-773.
33. Zaragoza O, Casadevall A. 2004. Experimental modulation of capsule size in Cryptococcus neoformans. Biol. Proced. Online 6:10-15.